Clinical Trials Logo

Allergic Conjunctivitis clinical trials

View clinical trials related to Allergic Conjunctivitis.

Filter by:

NCT ID: NCT02251613 Completed - Clinical trials for Allergic Conjunctivitis

Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan

Start date: December 2013
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the effectiveness and safety of Olopatadine Hydrochloride (HCl) ophthalmic solution 0.1% versus Epinastine HCl ophthalmic solution, 0.05% in a population of healthy, adult Japanese patients (20 years of age or older) with a history of allergic conjunctivitis to Japanese Cedar Pollen. Patients will be randomly assigned to receive Olopatadine HCl ophthalmic solution, 0.1% in one eye and Epinastine HCl ophthalmic solution, 0.05% in the fellow eye, after which a conjunctival allergy challenge (CAC) with Japanese cedar pollen will be performed.

NCT ID: NCT02148744 Completed - Atopic Dermatitis Clinical Trials

Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis

Start date: May 2014
Phase: Phase 1
Study type: Interventional

This first-in-human (FIH) study is a randomized, double-blinded, placebo-controlled, ascending dose study to investigate the safety, tolerability, and pharmacokinetics of XmAb7195 in adult healthy volunteers and in adult subjects with elevated IgE levels.

NCT ID: NCT02082899 Completed - Clinical trials for Allergic Conjunctivitis

A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1)

Start date: February 2014
Phase: Phase 2
Study type: Interventional

This is a Phase II Single Center, Randomized, Double-Masked, Vehicle-Controlled, Parallel, Group Study to Assess the Efficacy of EBI-005 Topical Ophthalmic Solution for the Treatment of Moderate to Severe Allergic Conjunctivitis Using an Environmental Exposure Chamber (EEC) Model and Conjunctival Allergen Provocation Test (CAPT) Model. Approximately 150 subjects will be enrolled and randomized in one study center in Canada for a duration of 0.33 years.

NCT ID: NCT02079649 Completed - Clinical trials for Allergic Conjunctivitis

Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for Allergic Conjunctivitis

Start date: April 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate two investigational ophthalmic solutions for reduction in ocular redness in subjects with allergic conjunctivitis.

NCT ID: NCT01881113 Completed - Clinical trials for Allergic Conjunctivitis

A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

Start date: June 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) model.

NCT ID: NCT01754766 Completed - Clinical trials for Allergic Conjunctivitis

AGN-229666 for the Treatment of Allergic Conjunctivitis

Start date: October 2012
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of AGN-229666 for the treatment of allergic conjunctivitis.

NCT ID: NCT01743027 Completed - Clinical trials for Allergic Conjunctivitis

Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis

Start date: January 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate an ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis using the Conjunctival Allergen Challenge (CAC) model.

NCT ID: NCT01731249 Completed - Allergic Rhinitis Clinical Trials

Efficacy and Safety Study of a Sublingual Immunotherapy Solution to Treat Patients Suffering From Birch Pollen Allergic Rhinoconjunctivitis

Start date: November 2010
Phase: Phase 3
Study type: Interventional

The purpose of this 2-year study is to assess the sustained clinical efficacy and safety of 300 IR/day of a sublingual solution of birch pollen allergen extract starting 4 months prior to the birch pollen season and continuing over the birch pollen season compared with placebo for reduction of rhinoconjunctivitis-related symptoms and anti-allergy medication usage.

NCT ID: NCT01698814 Completed - Clinical trials for Allergic Conjunctivitis

A Six-Week Safety Study of an Investigational Ophthalmic Solution

Start date: October 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the ocular safety of an investigational ophthalmic solution in subjects 2 years of age and older with asymptomatic eyes when administered once daily in both eyes for up to 6 weeks.

NCT ID: NCT01697969 Completed - Clinical trials for Allergic Conjunctivitis

Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients

Start date: September 2012
Phase: Phase 4
Study type: Interventional

The purpose of this study is to descriptively evaluate the corneal structures of allergic conjunctivitis patients.